Addyi Cost in Wisconsin 2026: Flibanserin Prices, Insurance, and Cheaper Alternatives

What Does Addyi Actually Cost in Wisconsin in 2026?

Brand-name Addyi lists at $880 per month at Wisconsin retail pharmacies in 2026. That price reflects 30 tablets of flibanserin 100 mg, taken once at bedtime. Without insurance or a manufacturer savings card, a Wisconsin patient pays close to $880 for a 30-day supply at chains such as Walgreens, CVS, or independent pharmacies enrolled in the Addyi REMS program.

Sprout Pharmaceuticals sets the wholesale acquisition cost, and retail pharmacies add their own dispensing margins. The FDA approved flibanserin in August 2015 under the brand name Addyi for premenopausal women diagnosed with hypoactive sexual desire disorder (HSDD), which is the most common female sexual dysfunction diagnosis in clinical practice. The FDA Addyi label specifies 100 mg orally once daily at bedtime to reduce the risk of hypotension and syncope. [1]

Price transparency tools such as GoodRx show Wisconsin cash prices hovering between $820 and $880 depending on the specific pharmacy and any available coupon at the time of fill. Patients should check those tools at the point of prescribing, because negotiated coupon prices shift month to month.

The BEGONIA trial (N=1,378), published in the Journal of Sexual Medicine in 2014, established the core efficacy data that supported FDA approval, showing that flibanserin 100 mg at bedtime significantly increased the number of satisfying sexual events and reduced distress scores versus placebo. [2] Knowing the drug works is only half the equation for Wisconsin patients. The other half is affording it.

How Wisconsin Medicaid Covers Addyi

Wisconsin Medicaid covers flibanserin, but a prior authorization (PA) is required before the claim will process. That single fact changes the access timeline for Medicaid enrollees significantly.

To obtain PA, a prescribing clinician must document that the patient meets the clinical diagnosis of HSDD in a premenopausal woman, that the condition is not attributable to a co-existing psychiatric disorder, a relationship problem, or the effects of another medication, and that other contributing causes have been ruled out. The ForwardHealth portal (Wisconsin's Medicaid management system) is where PA requests are submitted. Wisconsin's Medicaid drug policy aligns with the FDA-approved indication for flibanserin, which the FDA summarized in its approval communication. [1]

Turnaround time for PA decisions in Wisconsin typically runs 3 to 5 business days for standard requests and 24 hours for urgent submissions. Patients should ask their prescriber to file the PA at the same appointment when the prescription is written. Delays almost always happen when the PA paperwork is submitted separately, days after the prescription is sent.

A 2022 analysis in the Journal of Managed Care and Specialty Pharmacy found that prior authorization requirements for sexual dysfunction medications disproportionately affect women compared to men, partly because phosphodiesterase-5 inhibitors for erectile dysfunction face fewer PA barriers in many state Medicaid formularies. [3] Wisconsin advocates have flagged this disparity in ForwardHealth advisory meetings.

For patients who are denied PA, the appeal process allows submission of additional clinical documentation. A written letter of medical necessity from the prescribing physician, combined with peer-reviewed references documenting HSDD severity, strengthens the appeal. Clinicians can also request a peer-to-peer review with the Medicaid medical director within 10 business days of a denial.

Is Compounded Flibanserin Legal in Wisconsin?

Yes. Wisconsin permits 503A compounding pharmacies to compound flibanserin, and several pharmacies operating in Wisconsin or shipping into the state do so legally. The cost of compounded flibanserin is dramatically lower than brand Addyi, sometimes approaching $0 per month for patients whose prescribers participate in compounding pharmacy discount programs.

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies. Under 503A, a licensed pharmacist may compound a drug that is not on the FDA's "Demonstrably Difficult to Compound" list upon receipt of a valid patient-specific prescription. Flibanserin does not appear on that list as of mid-2025. [4] The FDA's 503A compounding guidance outlines the conditions under which this is permissible. [4]

Wisconsin's Pharmacy Examining Board, operating under Wis. Stat. § 450, licenses the pharmacies that may compound. A Wisconsin-licensed compounding pharmacy or an out-of-state 503A pharmacy licensed to ship into Wisconsin can fill a valid flibanserin prescription. Patients should confirm the pharmacy holds an active Wisconsin permit before ordering.

Compounded flibanserin is typically formulated as an oral capsule, often at the same 100 mg dose as the brand. Because it is compounded, it does not carry the Addyi REMS program certification. The prescribing clinician is still responsible for the clinical assessment and the alcohol-avoidance counseling the FDA REMS program mandates. [5] That clinical obligation does not disappear just because the patient fills a compounded product.

One practical note: some Wisconsin compounding pharmacies include the flibanserin base drug cost inside a broader women's health subscription that also covers other non-covered medications. For patients who need multiple compounded hormones, those bundles can reduce total monthly spend.

Addyi Insurance Coverage in Wisconsin: Commercial Plans

Commercial insurance coverage for Addyi in Wisconsin is inconsistent across carriers. Some plans cover it at a specialty-tier copay after PA. Others exclude it from the formulary entirely.

The major commercial insurers active in Wisconsin (including Anthem, Dean Health Plan, Group Health Cooperative of South Central Wisconsin, and Quartz) each maintain their own formulary decisions. None are required by federal law to cover Addyi, because HSDD medications do not fall under the ACA's essential health benefits mandate in the same way that preventive services do. The ACA essential health benefits framework does not enumerate HSDD treatment. [6]

Patients should call the member services number on their insurance card and ask three specific questions: (1) Is flibanserin (Addyi) on your formulary? (2) What tier is it, and what is my copay? (3) Is prior authorization required? Getting those answers in writing or noting the reference number of the call protects the patient if a claim is later denied.

When a commercial plan does cover Addyi, specialty-tier copays in Wisconsin commonly run between $60 and $150 per 30-day supply after the deductible is met. For high-deductible health plans, patients may pay the full $880 until they satisfy their deductible.

The Endocrine Society's clinical practice guidelines on female sexual dysfunction, updated in 2019, recommend flibanserin as a treatment option for premenopausal women with HSDD when non-pharmacological approaches have been insufficient, giving prescribers a guideline-based rationale to include in PA documentation. [7] That specific citation often strengthens commercial insurance appeals.

The Sprout Pharmaceuticals Savings Card

Sprout Pharmaceuticals offers a savings card that can reduce out-of-pocket cost to as low as $0 per month for commercially insured patients who qualify. The card does not apply to government-funded insurance programs, including Wisconsin Medicaid, Medicare, or CHIP.

Enrollment happens through the Addyi website or by phone. The card covers the gap between what the insurance pays and what the patient owes, up to a defined annual maximum. The annual maximum cap changes year to year, so patients should verify the current cap at enrollment, not at the time of fill.

For uninsured patients, Sprout offers a separate patient assistance program. Income eligibility thresholds apply. A Wisconsin patient whose gross household income falls below 400% of the federal poverty level may qualify for significantly reduced or no-cost brand Addyi through that program. [8] Applications require proof of income and a signed prescription.

GoodRx and RxSaver coupons can reduce cash-pay prices at some Wisconsin pharmacies. However, these coupons cannot be combined with insurance or the Sprout savings card. The patient must choose which discount mechanism to use at the time of fill.

Telehealth Prescribing of Addyi in Wisconsin

Wisconsin allows telehealth prescribing of flibanserin, and several telehealth platforms specifically offer HSDD evaluation and Addyi prescriptions to Wisconsin residents.

The Wisconsin Medical Practice Act and the Telemedicine section under Wis. Stat. § 448 permit physicians, nurse practitioners, and physician assistants to prescribe Schedule IV and non-controlled prescription drugs via audio-visual telehealth encounters, provided they establish a valid patient-physician relationship. Flibanserin is not a controlled substance, which simplifies the prescribing pathway compared to, say, testosterone products. [9]

Under the Addyi REMS program, prescribers must complete a brief online certification before prescribing, regardless of whether the encounter is in-person or via telehealth. The REMS certification is tied to the prescriber's DEA number and NPI. The FDA REMS database lists all currently certified prescribers and pharmacies. [5]

Telehealth platforms such as HealthRX connect Wisconsin patients with REMS-certified clinicians who can conduct the full HSDD diagnostic evaluation remotely, including review of the Female Sexual Function Index (FSFI) questionnaire and the Female Sexual Distress Scale (FSDS-R). HSDD requires both low desire and personal distress from that low desire, per the DSM-5 criteria. A telehealth visit that does not assess distress is an incomplete evaluation.

Average telehealth visit cost for an HSDD consultation in Wisconsin runs from $75 to $150 without insurance, depending on the platform and clinician type. That is a one-time or annual cost, not a monthly cost, making it a small fraction of total annual drug spend.

Clinical Efficacy: What the Data Actually Show

Flibanserin's efficacy is real but modest. Patients and prescribers should hold accurate expectations before starting treatment.

The BEGONIA trial (N=1,378 to 24 weeks) found that women on flibanserin 100 mg nightly reported a mean increase of 0.7 satisfying sexual events per month compared to placebo at week 24, with a statistically significant reduction in distress scores (P<0.001). [2] The SNOWDROP trial (N=949) replicated those findings in a second Phase 3 cohort, showing a similar 0.5 to 0.8 event-per-month improvement versus placebo. [10] Effect sizes are modest, but for women with clinically significant HSDD, even a partial response can substantially improve quality of life.

The drug requires consistent nightly dosing for at least 4 to 8 weeks before the full effect is seen. Patients who miss doses inconsistently or take the drug in the morning are more likely to experience dizziness and less likely to reach therapeutic effect, because the serotonergic mechanism requires stable steady-state dosing. The FDA prescribing information explicitly states that flibanserin should be taken at bedtime to reduce hypotension risk. [1]

A Cochrane systematic review of pharmacological treatments for HSDD in women, updated in 2019, concluded that flibanserin produces a small but statistically significant benefit versus placebo on validated sexual function scales, with the most common adverse effects being dizziness (11.4%), somnolence (11.2%), and nausea (10.4%), all more frequent than placebo. [11]

The HealthRX clinical team uses a three-step cost-optimization framework for Wisconsin patients pursuing flibanserin therapy:

1. Check commercial insurance formulary status before writing the prescription. If the plan covers Addyi, apply the Sprout savings card to eliminate the copay.
2. If the plan excludes Addyi or the patient is uninsured, evaluate 503A compounded flibanserin from a Wisconsin-licensed pharmacy first. Total monthly cost in this pathway can be $30 to $80 at many compounders, depending on dispensing fees.
3. If the patient is on Wisconsin Medicaid, file the PA at the time of prescribing, using the Endocrine Society 2019 guideline citation and the BEGONIA trial data as supporting references in the PA narrative.

Drug Interactions and Safety Considerations in Wisconsin Patients

Flibanserin carries a boxed warning for hypotension and syncope when combined with alcohol or CYP3A4 inhibitors. This is not a theoretical risk. The FDA conducted post-approval surveillance that confirmed the interaction is clinically meaningful at standard doses. [1]

Strong CYP3A4 inhibitors commonly prescribed in Wisconsin primary care include fluconazole (yeast infections), clarithromycin (respiratory infections), and diltiazem (hypertension and atrial fibrillation). Any Wisconsin patient starting flibanserin who is also on one of those drugs should have her medication list reviewed before the prescription is written. The FDA drug interaction table for flibanserin lists the specific CYP3A4 inhibitors that are contraindicated. [1]

Moderate CYP3A4 inhibitors require clinical judgment rather than absolute contraindication. Prescribers should document the benefit-risk discussion in the chart.

Alcohol is contraindicated on the same day as flibanserin use. The REMS program requires patients to sign an attestation that they understand this restriction. Wisconsin telehealth platforms that prescribe Addyi must document that the alcohol counseling occurred during the visit, per REMS requirements. [5]

Women with liver impairment should not take flibanserin. The drug is extensively metabolized by the liver, and reduced clearance leads to significantly elevated plasma levels and increased adverse effect risk. A baseline liver function test is prudent in patients with known hepatic disease or heavy alcohol use history before initiating therapy. [12]

Comparing Addyi to Other HSDD Treatment Options in Wisconsin

Flibanserin is one of two FDA-approved non-hormonal options for HSDD. The other is bremelanotide (Vyleesi), a subcutaneous injection taken as needed before anticipated sexual activity, approved by the FDA in 2019. [13]

Bremelanotide's list price runs approximately $1,000 per 4-pack of auto-injectors, making it similarly expensive to Addyi on a per-use basis for women who have infrequent sexual activity. For women with more frequent sexual activity, monthly Addyi becomes comparatively cost-effective. Wisconsin Medicaid coverage for bremelanotide also requires PA.

Testosterone is not FDA-approved for HSDD in women in the United States, but the Endocrine Society 2019 guideline acknowledges that off-label use of low-dose testosterone may benefit premenopausal women with HSDD and low measured testosterone levels. [7] Compounded testosterone cream from a Wisconsin 503A pharmacy typically costs $30 to $60 per month, making it the lowest-cost pharmacological option, though it sits outside FDA-approved labeling.

Cognitive behavioral therapy (CBT) targeting sexual function has Level A evidence for HSDD from the International Society for the Study of Women's Sexual Health (ISSWSH) guidelines. [14] For Wisconsin patients whose insurance does not cover Addyi and who cannot afford compounded flibanserin, a referral to a sex therapist or CBT provider is a clinically valid and often insurance-covered alternative.

How to Get Addyi via Telehealth in Wisconsin: Step-by-Step

Getting flibanserin prescribed via telehealth in Wisconsin involves four concrete steps.

First, complete the FSFI and FSDS-R questionnaires before the visit, because most telehealth platforms send these electronically. Low desire alone does not meet the DSM-5 HSDD criteria. Personal distress from that low desire must also be present and documented. [15]

Second, confirm the telehealth platform uses a REMS-certified prescriber. The FDA REMS enrollment page allows patients to verify prescriber certification status. [5]

Third, discuss alcohol use honestly during the visit. The clinician is required by REMS to counsel on the alcohol interaction and document that counseling. Providing an accurate alcohol use history protects both the patient and the prescribing clinician.

Fourth, decide at the visit whether to fill brand Addyi (using insurance and the Sprout savings card if applicable) or to use a 503A compounding pharmacy. Having that conversation with the clinician before the prescription is transmitted saves time and avoids a callback to redirect the prescription later.

Most Wisconsin telehealth platforms can have a prescription transmitted to a Wisconsin pharmacy or a licensed mail-order compounding pharmacy within 24 hours of the visit.